Based on these data, de novo protein synthesis is not required for E2F1-induced upregulation of these genes, underscoring that they are direct targets of E2F1

Based on these data, de novo protein synthesis is not required for E2F1-induced upregulation of these genes, underscoring that they are direct targets of E2F1. == Fig.4. that TIEG1/KLF10 is definitely transcriptionally triggered by E2F1 and important for E2F1-mediated chemosensitization of malignancy cells. Our results provide a broader picture of E2F1-controlled genes in conjunction with cytotoxic treatment that allows the design of more rational therapeutics. Keywords:E2F1, Chemotherapy, Assistance response genes, TIEG1/KLF10, Cell death, Cancer == Intro == A critical determinant of the effectiveness of antineoplastic therapy is the ability of malignant cells to undergo apoptosis in response to DNA damage induced by chemotherapeutic providers. The success of genotoxic treatments is definitely attributed, at least in part, to the fact that DNA damage induces cell death more readily in malignancy cells than in normal cells. The molecular mechanism(s) underlying this enhanced level of sensitivity of malignancy cells to chemotherapy-induced apoptosis are not fully recognized. In this regard, the cellular transcription element E2F1, which is frequently upregulated in neoplastic cells, appears to be of particular significance. E2F regulates cell cycle progression by coordinating genes that promote G1- to S-phase transition [1]. Beside its well-established function as a proliferative element contributing to malignant transformation of main rodent cells and tumorgenesis in mice (examined in [2]), ectopic manifestation of E2F1 prospects to high levels of apoptosis [3]. E2F1 knockout mice show problems in thymocyte apoptosis and have a high incidence of tumor development [4,5], providing evidence that E2F1 serves as a tumor suppressor in vivo. Apoptosis linked to E2F1 is certainly mediated within a p53-reliant and p53-indie manner (analyzed in [6]). Generally, induction of cell loss of life by E2F1 takes place via immediate transcriptional activation of proapoptotic genes, including p14ARF [7], p73 [8,9], Apaf-1 [10], BH3-just proteins [11], and caspases [12], or through inhibition of success and antiapoptotic signaling mediated by NF-B [13], Bcl-2 [14], and GRP78 [15]. Although E2F2 and E2F3 induce apoptosis also, this effect is certainly modest in comparison to E2F1, and regarding E2F3, related to its capability to transactivate the E2F1 gene [12] largely. Like p53, E2F1 is certainly an essential determinant from the mobile response to DNA harm. Its apoptotic activity is certainly induced by DNA harm [16], and aberrant appearance from the transcription aspect has been proven to improve the awareness of specific neoplastic cell types to apoptosis when treated with ionizing rays or chemotherapeutic agencies [1724]. In response to genotoxic tension, the E2F1 proteins is certainly stabilized through immediate phosphorylation by Chk2 and ATM/ATR [25,26]. Because E2F1 features upstream of the kinases by transcriptionally regulating their appearance also, DNA harm sets off a positive-feedback loop between ATM/Chk2 and E2F1 [2729]. In keeping with the selective deposition of E2F1 proteins during DNA harm, ATM/ATR usually do not phosphorylate E2F2 or E2F3 [25]. Furthermore, E2F1 stabilization during DNA harm takes place by binding of 14-3-3 proteins to phosphorylated E2F1, which inhibits its ubiquitination [30]. E2F1 activation upon genotoxic tension is due to acetylation also. DNA harm sets off P/CAF (p300/CREB-binding proteins associated aspect) to bind and acetylate E2F1 [31]. This adjustment affects the DNA-binding activity and transactivation potential of E2F1 particularly, and continues to be suggested to have an effect on its focus on promoter selectivity, favoring induction of proapoptotic genes such as for example p73 [3133]. Furthermore, Chk2 and Chk1 are necessary for p73 deposition after DNA harm, recommending their potential function in p53-indie sensitization of cancers cells to cytotoxic medications induced by deregulated E2F1 [34]. Predicated on latest results, microcephalin (MCPH1) cooperates with E2F1 by complicated formation in the Chk1 and p73 promoter, and regulates induction and appearance of both genes during DNA harm and E2F1-dependent apoptosis [35]. Regarding our previous research demonstrating an optimistic relationship between E2F1 overexpression, awareness to medically relevant medications, and reduced amount of p53-deficient tumors in vivo [18], this stresses the healing potential of downstream mediators of E2F1-induced chemosensitization. Nevertheless, the molecular mechanisms underlying the cooperative effect are unidentified generally. Due to the fact E2F1 handles the transcription Indigo of many genes, we elucidated Indigo modifications in gene appearance information of chemoresistant osteosarcoma and pancreatic cancers cells subjected to elevated endogenous E2F1 and in medications focusing on co-operation response genes (CRGs). == Components and strategies == == Cell lines, genotoxic remedies and inhibition of proteins de novo synthesis == Maintenance of Saos-2 and Saos-2.ER-E2F1 cells continues to be described [8] previously. The SK-Mel-147 cell series was provided.Both cell lines stably express the ER-E2F1 fusion protein to conditionally regulate E2F1 activation through 4-OHT (4-hydroxytamoxifen) administration [38]. as immediate E2F1 targets. That TIEG1/KLF10 is showed by us is transcriptionally activated by E2F1 and essential for E2F1-mediated chemosensitization of cancer cells. Our results give a broader picture of E2F1-governed genes together with cytotoxic treatment which allows the look of more logical therapeutics. Keywords:E2F1, Chemotherapy, Co-operation response genes, TIEG1/KLF10, Cell loss of life, Cancer == Launch == A crucial determinant from the efficiency of antineoplastic therapy may be the capability of malignant cells to endure apoptosis in response to DNA harm induced by chemotherapeutic agencies. The achievement of genotoxic remedies is certainly attributed, at least partly, to the actual fact that DNA harm induces cell loss of life more easily in cancers cells than in regular cells. The molecular system(s) root this enhanced awareness of cancers cells to chemotherapy-induced apoptosis aren’t fully grasped. In this respect, the mobile transcription aspect E2F1, which is generally upregulated in neoplastic cells, is apparently of particular significance. E2F regulates cell routine development by coordinating genes that promote G1- to S-phase changeover [1]. Beside its well-established work as a proliferative aspect adding to malignant change of principal rodent cells and tumorgenesis in mice (analyzed in [2]), ectopic appearance of E2F1 network marketing leads to high degrees of apoptosis [3]. E2F1 Indigo knockout mice display flaws in thymocyte apoptosis and have a high incidence of tumor development [4,5], providing evidence that E2F1 acts as a tumor suppressor in vivo. Apoptosis related to E2F1 is usually mediated in a p53-dependent and p53-impartial manner (reviewed in [6]). In most cases, induction of cell death by E2F1 occurs via direct transcriptional activation of proapoptotic genes, including p14ARF [7], p73 [8,9], Apaf-1 [10], BH3-only proteins [11], and caspases [12], or through inhibition of survival and antiapoptotic signaling mediated by NF-B [13], Bcl-2 [14], and GRP78 [15]. Although E2F2 and E2F3 also induce apoptosis, this effect is usually modest compared to E2F1, and in the case of E2F3, largely attributed to its ability to transactivate the E2F1 gene [12]. Like p53, E2F1 is usually a crucial determinant of TNFRSF11A the cellular response to DNA damage. Its apoptotic activity is usually induced by DNA damage [16], and aberrant expression of the transcription factor has been shown to increase the sensitivity of certain neoplastic cell types to apoptosis when treated with ionizing radiation or chemotherapeutic brokers [1724]. In response to genotoxic stress, the E2F1 protein is usually stabilized through direct phosphorylation by ATM/ATR and Chk2 [25,26]. Because E2F1 also functions upstream of these kinases by transcriptionally regulating their expression, DNA damage triggers a positive-feedback loop between E2F1 and ATM/Chk2 [2729]. Consistent with the selective accumulation of E2F1 protein during DNA damage, ATM/ATR do not phosphorylate E2F2 or E2F3 [25]. In addition, E2F1 stabilization during DNA damage occurs by binding of 14-3-3 proteins to phosphorylated E2F1, which inhibits its ubiquitination [30]. E2F1 activation upon genotoxic stress is also caused by acetylation. DNA damage triggers P/CAF (p300/CREB-binding protein associated factor) to bind and acetylate E2F1 [31]. This modification specifically influences the DNA-binding activity and transactivation potential of E2F1, and has been suggested to affect its target promoter selectivity, favoring induction of proapoptotic genes such as p73 [3133]. Furthermore, Chk1 and Chk2 are required for p73 accumulation after DNA damage, suggesting their potential role in p53-impartial sensitization of cancer cells to cytotoxic drugs induced by deregulated E2F1 [34]. Based on recent findings, microcephalin (MCPH1) cooperates with E2F1 by complex formation around the Chk1 and p73 promoter, and regulates expression and induction of both genes during DNA damage and E2F1-dependent apoptosis [35]. With respect to our previous studies demonstrating a positive correlation between E2F1 overexpression, sensitivity to clinically relevant drugs, and reduction of p53-deficient tumors in vivo [18], this emphasizes the therapeutic potential of downstream mediators of E2F1-induced chemosensitization. However, the molecular mechanisms underlying the cooperative effect are largely unknown. Considering that E2F1 controls the transcription of several genes, we elucidated alterations in gene expression profiles of chemoresistant osteosarcoma and pancreatic cancer cells exposed to increased endogenous E2F1 and in drug treatment focusing on cooperation response genes (CRGs). == Materials and methods == == Cell lines, genotoxic treatments and inhibition of protein de novo synthesis == Maintenance of Saos-2 and Saos-2.ER-E2F1 cells has been described previously [8]. The SK-Mel-147 cell line was kindly provided by Dr. M.S. Soengas (Department of Dermatology, University of Michigan, Comprehensive Cancer Center, Ann Arbor, MI, USA) and cultured as indicated [36]. MZA pancreas adenocarcinoma cells (obtained from D.I. Smith, Mayo Clinic, Rochester, MN, USA) were maintained in Dulbeccos modified Eagle medium (high glucose, 4.5 g/l) supplemented with 10% fetal bovine serum, 100 U/mL penicillin,.As illustrated in Fig.5b, the KLF10 DNA probe gave retarded bands of strong intensities with nuclear extracts from Saos-2.ER-E2F1 cells after E2F1 activation (lane 2). picture of E2F1-regulated genes in conjunction with cytotoxic treatment that allows the design of more rational therapeutics. Keywords:E2F1, Chemotherapy, Cooperation response genes, TIEG1/KLF10, Cell death, Cancer == Introduction == A critical determinant of the efficacy of antineoplastic therapy is the ability of malignant cells to undergo apoptosis in response to DNA damage induced by chemotherapeutic brokers. The success of genotoxic treatments is usually attributed, at least in part, to the fact that DNA damage induces cell death more readily in cancer cells than in normal cells. The molecular mechanism(s) underlying this enhanced sensitivity of cancer cells to chemotherapy-induced apoptosis are not fully comprehended. In this regard, the cellular transcription factor E2F1, which is frequently upregulated in neoplastic cells, appears to be of particular significance. E2F regulates cell cycle progression by coordinating genes that promote G1- to S-phase transition [1]. Beside its well-established function as a proliferative factor contributing to malignant transformation of primary rodent cells and tumorgenesis in mice (reviewed in [2]), ectopic expression of E2F1 leads to high levels of apoptosis [3]. E2F1 knockout mice exhibit defects in thymocyte apoptosis and have a high incidence of tumor development [4,5], providing evidence that E2F1 acts as a tumor suppressor in vivo. Apoptosis related to E2F1 is usually mediated in a p53-dependent and p53-impartial manner (reviewed in [6]). In most cases, induction of cell death by E2F1 occurs via direct transcriptional activation of proapoptotic genes, including p14ARF [7], p73 [8,9], Apaf-1 [10], BH3-only proteins [11], and caspases [12], or through inhibition of survival and antiapoptotic signaling mediated by NF-B [13], Bcl-2 [14], and GRP78 [15]. Although E2F2 and E2F3 also induce apoptosis, this effect is usually modest compared to E2F1, and in the case of E2F3, largely attributed to its ability to transactivate the E2F1 gene [12]. Like p53, E2F1 is usually a crucial determinant of the cellular response to DNA damage. Its apoptotic activity is usually induced by DNA damage [16], and aberrant expression of the transcription factor has been shown to increase the sensitivity of certain neoplastic cell types to apoptosis when treated with ionizing radiation or chemotherapeutic brokers [1724]. In response to genotoxic stress, the E2F1 protein is usually stabilized through direct phosphorylation by ATM/ATR and Chk2 [25,26]. Because E2F1 also functions upstream of these kinases by transcriptionally regulating their expression, DNA damage triggers a positive-feedback loop between E2F1 and ATM/Chk2 [2729]. Consistent with the selective accumulation of E2F1 protein during DNA damage, ATM/ATR do not phosphorylate E2F2 or E2F3 [25]. In addition, E2F1 stabilization during DNA damage occurs by binding of 14-3-3 proteins to phosphorylated E2F1, which inhibits its ubiquitination [30]. E2F1 activation upon genotoxic stress is also caused by acetylation. DNA damage triggers P/CAF (p300/CREB-binding protein associated factor) to bind and acetylate E2F1 [31]. This modification specifically influences the DNA-binding activity and transactivation potential of E2F1, and has been suggested to affect its target promoter selectivity, favoring induction of proapoptotic genes such as p73 [3133]. Furthermore, Chk1 and Chk2 are required for p73 accumulation after DNA damage, suggesting their potential role in p53-impartial sensitization of cancer cells to cytotoxic drugs induced by deregulated E2F1 [34]. Based on recent findings, microcephalin (MCPH1) cooperates with E2F1 by complex formation on the Chk1 and p73 promoter, and regulates expression and induction of both genes during DNA damage and E2F1-dependent apoptosis Indigo [35]. With respect to our previous studies demonstrating a positive correlation between E2F1 overexpression, sensitivity to clinically relevant drugs, and reduction of p53-deficient tumors.Based on these data, de novo protein synthesis is not required for E2F1-induced upregulation of these genes, underscoring that they are direct targets of E2F1. == Fig.4. that TIEG1/KLF10 is definitely transcriptionally triggered by E2F1 and important for E2F1-mediated chemosensitization of malignancy cells. Our results provide a broader picture of E2F1-controlled genes in conjunction with cytotoxic treatment that allows the design of more rational therapeutics. Keywords:E2F1, Chemotherapy, Assistance response genes, TIEG1/KLF10, Cell death, Cancer == Intro == A critical determinant of the effectiveness of antineoplastic therapy is the ability of malignant cells to undergo apoptosis in response to DNA damage induced by chemotherapeutic providers. The success of genotoxic treatments is definitely attributed, at least in part, to the fact that DNA damage induces cell death more readily in malignancy cells than in normal cells. The molecular mechanism(s) underlying this enhanced level of sensitivity of malignancy cells to chemotherapy-induced apoptosis are not fully recognized. In this regard, the cellular transcription element E2F1, which is frequently upregulated in neoplastic cells, appears to be of particular significance. E2F regulates cell cycle progression by coordinating genes that promote G1- to S-phase transition [1]. Beside its well-established function as a proliferative element contributing to malignant transformation of main rodent cells and tumorgenesis in mice (examined in [2]), ectopic manifestation of E2F1 prospects to high levels of apoptosis [3]. E2F1 knockout mice show problems in thymocyte apoptosis and have a high incidence of tumor development [4,5], providing evidence that E2F1 serves as a tumor suppressor in vivo. Apoptosis linked to E2F1 is certainly mediated within a p53-reliant and p53-indie manner (analyzed in [6]). Generally, induction of cell loss of life by E2F1 takes place via immediate transcriptional activation of proapoptotic genes, including p14ARF [7], p73 [8,9], Apaf-1 [10], BH3-just proteins [11], and caspases [12], or through inhibition of success and antiapoptotic signaling mediated by NF-B [13], Bcl-2 [14], and GRP78 [15]. Although E2F2 and E2F3 induce apoptosis also, this effect is certainly modest in comparison to E2F1, and regarding E2F3, related to its capability to transactivate the E2F1 gene [12] largely. Like p53, E2F1 is certainly an essential determinant from the mobile response to DNA harm. Its apoptotic activity is certainly induced by DNA harm [16], and aberrant appearance from the transcription aspect has been proven to improve the awareness of specific neoplastic cell types to apoptosis when treated with ionizing rays or chemotherapeutic agencies [1724]. In response to genotoxic tension, the E2F1 proteins is certainly stabilized through immediate phosphorylation by Chk2 and ATM/ATR [25,26]. Because E2F1 features upstream of the kinases by transcriptionally regulating their appearance also, DNA harm sets off a positive-feedback loop between ATM/Chk2 and E2F1 [2729]. In keeping with the selective deposition of E2F1 proteins during DNA harm, ATM/ATR usually do not phosphorylate E2F2 or E2F3 [25]. Furthermore, E2F1 stabilization during DNA harm takes place by binding of 14-3-3 proteins to phosphorylated E2F1, which inhibits its ubiquitination [30]. E2F1 activation upon genotoxic tension is due to acetylation also. DNA harm sets off P/CAF (p300/CREB-binding proteins associated aspect) to bind and acetylate E2F1 [31]. This adjustment affects the DNA-binding activity and transactivation potential of E2F1 particularly, and continues to be suggested to have an effect on its focus on promoter selectivity, favoring induction of proapoptotic genes such as for example p73 [3133]. Furthermore, Chk2 and Chk1 are necessary for p73 deposition after DNA harm, recommending their potential function in p53-indie sensitization of cancers cells to cytotoxic medications induced by deregulated E2F1 [34]. Predicated on latest results, microcephalin (MCPH1) cooperates with E2F1 by complicated formation in the Chk1 and p73 promoter, and regulates induction and appearance of both genes during DNA harm and E2F1-dependent apoptosis [35]. Regarding our previous research demonstrating an optimistic relationship between E2F1 overexpression, VULM 1457 awareness to medically relevant medications, and reduced amount of p53-deficient tumors in vivo [18], this stresses the healing potential of downstream mediators of E2F1-induced chemosensitization. Nevertheless, the molecular mechanisms underlying the cooperative effect are unidentified generally. Due to the fact E2F1 handles the transcription of many genes, we elucidated modifications in gene appearance information of chemoresistant osteosarcoma and pancreatic cancers cells subjected to elevated endogenous E2F1 and in medications focusing on co-operation response genes (CRGs). == Components and strategies == == Cell lines, genotoxic remedies and inhibition of proteins de novo synthesis == Maintenance of Saos-2 and Saos-2.ER-E2F1 Rabbit Polyclonal to HBP1 cells continues to be described [8] previously. The SK-Mel-147 cell series was provided.Both cell lines stably express the ER-E2F1 fusion protein to conditionally regulate E2F1 activation through 4-OHT (4-hydroxytamoxifen) administration [38]. as immediate E2F1 targets. That TIEG1/KLF10 is showed by us is transcriptionally activated by E2F1 and essential for E2F1-mediated chemosensitization of cancer cells. Our results give a broader picture of E2F1-governed genes together with cytotoxic treatment which allows the look of more logical therapeutics. Keywords:E2F1, Chemotherapy, Co-operation response genes, TIEG1/KLF10, Cell loss of life, Cancer == Launch == A crucial determinant from the efficiency of antineoplastic therapy may be the capability of malignant cells to endure apoptosis in response to DNA harm induced by chemotherapeutic agencies. The achievement of genotoxic remedies is certainly attributed, at least partly, to the actual fact that DNA harm induces cell loss of life more easily in cancers cells than in regular cells. The molecular system(s) root this enhanced awareness of cancers cells to chemotherapy-induced apoptosis aren’t fully grasped. In this respect, the mobile transcription aspect E2F1, which is generally upregulated in neoplastic cells, is apparently of particular significance. E2F regulates cell routine development by coordinating genes that promote G1- to S-phase changeover [1]. Beside its well-established work as a proliferative aspect adding to malignant change of principal rodent cells and tumorgenesis in mice (analyzed in [2]), ectopic appearance of E2F1 network marketing leads to high degrees of apoptosis [3]. E2F1 knockout mice display flaws in thymocyte apoptosis and have a high incidence of tumor development [4,5], providing VULM 1457 evidence that E2F1 acts as a tumor suppressor in vivo. Apoptosis related to E2F1 is usually mediated in a p53-dependent and p53-impartial manner (reviewed in [6]). In most cases, induction of cell death by E2F1 occurs via direct transcriptional activation of proapoptotic genes, including p14ARF [7], p73 [8,9], Apaf-1 [10], BH3-only proteins [11], and caspases [12], or through inhibition of survival and antiapoptotic signaling mediated by NF-B [13], Bcl-2 [14], and GRP78 [15]. Although E2F2 and E2F3 also induce apoptosis, this effect is usually modest compared to E2F1, and in the case of E2F3, largely attributed to its ability to transactivate the E2F1 gene [12]. Like p53, E2F1 is usually a crucial determinant of the cellular response to DNA damage. Its apoptotic activity is usually induced by DNA damage [16], and aberrant expression of the transcription factor has been shown to increase the sensitivity of certain neoplastic cell types to apoptosis when treated with ionizing radiation or chemotherapeutic brokers [1724]. In response to genotoxic stress, the E2F1 protein is usually stabilized through direct phosphorylation by ATM/ATR and Chk2 [25,26]. Because E2F1 also functions upstream of these kinases by transcriptionally regulating their expression, DNA damage triggers a positive-feedback loop between E2F1 and ATM/Chk2 [2729]. Consistent with the selective accumulation of E2F1 protein during DNA damage, ATM/ATR do not phosphorylate E2F2 or E2F3 [25]. In addition, E2F1 stabilization during DNA damage occurs by binding of 14-3-3 proteins to phosphorylated E2F1, which inhibits its ubiquitination [30]. E2F1 activation upon genotoxic stress is also caused by acetylation. DNA damage triggers P/CAF (p300/CREB-binding protein associated factor) to bind and acetylate E2F1 [31]. This modification specifically influences the DNA-binding activity and transactivation potential of E2F1, and has been suggested to affect its target promoter selectivity, favoring induction of proapoptotic genes such as p73 [3133]. Furthermore, Chk1 and Chk2 are required for p73 accumulation after DNA damage, suggesting their potential role in p53-impartial sensitization of cancer cells to cytotoxic drugs induced by deregulated E2F1 [34]. Based on recent findings, microcephalin (MCPH1) cooperates with E2F1 by complex formation around the Chk1 and p73 promoter, and regulates expression and induction of both genes during DNA damage and E2F1-dependent apoptosis [35]. With respect to our previous studies demonstrating a positive correlation between E2F1 overexpression, sensitivity to clinically relevant drugs, and reduction of p53-deficient tumors in vivo [18], this emphasizes the therapeutic potential of downstream mediators of E2F1-induced chemosensitization. However, the molecular mechanisms underlying the cooperative effect are largely unknown. Considering that E2F1 controls the transcription of several genes, we elucidated alterations in gene expression profiles of chemoresistant osteosarcoma and pancreatic cancer cells exposed to increased endogenous E2F1 and in drug treatment focusing on cooperation response genes VULM 1457 (CRGs). == Materials and methods == == Cell lines, genotoxic treatments and inhibition of protein de novo synthesis == Maintenance of Saos-2 and Saos-2.ER-E2F1 cells has been described previously [8]. The SK-Mel-147 cell line was kindly provided by Dr. M.S. Soengas (Department of Dermatology, University of Michigan, Comprehensive Cancer Center, Ann Arbor, MI, USA) and cultured as indicated [36]. MZA pancreas adenocarcinoma cells (obtained from D.I. Smith, Mayo Clinic, Rochester, MN, USA) were maintained in Dulbeccos modified Eagle medium (high glucose, 4.5 g/l) supplemented with 10% fetal bovine serum, 100 U/mL penicillin,.As illustrated in Fig.5b, the KLF10 DNA probe gave retarded bands of strong intensities with nuclear extracts from Saos-2.ER-E2F1 cells after E2F1 activation (lane 2). picture of E2F1-regulated genes in conjunction with cytotoxic treatment that allows the design of more rational therapeutics. Keywords:E2F1, Chemotherapy, Cooperation response genes, TIEG1/KLF10, Cell death, Cancer == Introduction == A critical determinant of the efficacy of antineoplastic therapy is the ability of malignant cells to undergo apoptosis in response to DNA damage induced by chemotherapeutic brokers. The success of genotoxic treatments is usually attributed, at least in part, to the fact that DNA damage induces cell death more readily in cancer cells than in normal cells. The molecular mechanism(s) underlying this enhanced sensitivity of cancer cells to chemotherapy-induced apoptosis are not fully comprehended. In this regard, the cellular transcription factor E2F1, which is frequently upregulated in neoplastic cells, appears to be of particular significance. E2F regulates cell cycle progression by coordinating genes that promote G1- to S-phase transition [1]. Beside its well-established function as a proliferative factor contributing to malignant transformation of primary rodent cells and tumorgenesis in mice (reviewed in [2]), ectopic expression of E2F1 leads to high levels of VULM 1457 apoptosis [3]. E2F1 knockout mice exhibit defects in thymocyte apoptosis and have a high incidence of tumor development [4,5], providing evidence that E2F1 acts as a tumor suppressor in vivo. Apoptosis related to E2F1 is usually mediated in a p53-dependent and p53-impartial manner (reviewed in [6]). In most cases, induction of cell death by E2F1 occurs via direct transcriptional activation of proapoptotic genes, including p14ARF [7], p73 [8,9], Apaf-1 [10], BH3-only proteins [11], and caspases [12], or through inhibition of survival and antiapoptotic signaling mediated by NF-B [13], Bcl-2 [14], and GRP78 [15]. Although E2F2 and E2F3 also induce apoptosis, this effect is usually modest compared to E2F1, and in the case of E2F3, largely attributed to its ability to transactivate the E2F1 gene [12]. Like p53, E2F1 is usually a crucial determinant of the cellular response to DNA damage. Its apoptotic activity is usually induced by DNA damage [16], and aberrant expression of the transcription factor has been shown to increase the sensitivity of certain neoplastic cell types to apoptosis when treated with ionizing radiation or chemotherapeutic brokers [1724]. In response to genotoxic stress, the E2F1 protein is usually stabilized through direct phosphorylation by ATM/ATR and Chk2 [25,26]. Because E2F1 also functions upstream of these kinases by transcriptionally regulating their expression, DNA damage triggers a positive-feedback loop between E2F1 and ATM/Chk2 [2729]. Consistent with the selective accumulation of E2F1 protein during DNA damage, ATM/ATR do not phosphorylate E2F2 or E2F3 [25]. In addition, E2F1 stabilization during DNA damage occurs by binding of 14-3-3 proteins to phosphorylated E2F1, which inhibits its ubiquitination [30]. E2F1 activation upon genotoxic stress is also caused by acetylation. DNA damage triggers P/CAF (p300/CREB-binding protein associated factor) to bind and acetylate E2F1 [31]. This modification specifically influences the DNA-binding activity and transactivation potential of E2F1, and has been suggested to affect its target promoter selectivity, favoring induction of proapoptotic genes such as p73 [3133]. Furthermore, Chk1 and Chk2 are required for p73 accumulation after DNA damage, suggesting their potential role in p53-impartial sensitization of cancer cells to cytotoxic drugs induced by deregulated E2F1 [34]. Based on recent findings, microcephalin (MCPH1) cooperates with E2F1 by complex formation on the Chk1 and p73 promoter, and regulates expression and induction of both genes during DNA damage and E2F1-dependent apoptosis [35]. With respect to our previous studies demonstrating a positive correlation between E2F1 overexpression, sensitivity to clinically relevant drugs, and reduction of p53-deficient tumors.